Clinical Trials Logo

Filter by:
NCT ID: NCT06101017 Recruiting - Corneal Disease Clinical Trials

Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease

Start date: October 12, 2023
Phase:
Study type: Observational

The goal is to develop a nationwide registry to track longitudinal clinical outcomes of and store imaging data related to numerous corneal conditions. There are two main objectives including the establishment of the first nationwide corneal transplant registry in the United States to include information related to the donor tissue, recipient, surgical procedure, and long-term clinical outcomes. Ultimately, this prospective data collection will allow us to determine prognostic factors for successful corneal transplantation and create an algorithm to guide clinical practice based on real world outcomes. The second objective is to collect and create a database of historical, de-identified optical coherence topography (OCT) and corneal topography images to ultimately develop artificial intelligence (AI) based diagnostic and prognostic algorithms for corneal disease and surgery.

NCT ID: NCT06101004 Not yet recruiting - Stroke Clinical Trials

A Multi-center, Non-interventional Prospective Clinical Trial to Evaluate the Safety and Effectiveness of CVA-FLOW

Start date: October 23, 2023
Phase:
Study type: Observational

CVAid Medical Ltd. developed a smartphone-based tele stroke system named CVA-Flow. This system aims to evaluate the patient's neurological status, particularly detection of a possible stroke, assessment of stroke severity, and prediction of LVO as the cause of stroke. The system's app guides the user through the examination step by step based on NIHSS/ Rapid Arterial Occlusion Evaluation (RACE) scales. The video can also be transferred offline to enable a distant stroke physician to assess the patient's status manually.

NCT ID: NCT06100991 Recruiting - Clinical trials for Generalized Pustular Psoriasis

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Start date: September 19, 2023
Phase:
Study type: Observational

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

NCT ID: NCT06100952 Recruiting - Keratoconus Clinical Trials

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Apricity-B
Start date: November 1, 2023
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT ID: NCT06100939 Recruiting - Keratoconus Clinical Trials

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Apricity-A
Start date: October 30, 2023
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT ID: NCT06100913 Not yet recruiting - Ebola Virus Disease Clinical Trials

Immunology of Ebola Vaccine

Start date: July 2024
Phase: Phase 2
Study type: Interventional

In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to assess immune responses in the blood, lymph nodes, and bone marrow over multiple time points.

NCT ID: NCT06100887 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (FOX)

Start date: March 22, 2024
Phase: Phase 2
Study type: Interventional

The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.

NCT ID: NCT06100874 Recruiting - Clinical trials for Breast Cancer Female

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Start date: November 20, 2023
Phase: Phase 2
Study type: Interventional

This research study is being done to evaluate the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer. The names of the study drugs used in this research study are: - Sacituzumab govitecan (a type of antibody-drug conjugate) - Trastuzumab (Herceptin) (a type of monoclonal antibody) - Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) (a type of recombinant monoclonal antibody) - Trastuzumab biosimilar drug

NCT ID: NCT06100822 Recruiting - Chronic Pain Clinical Trials

Managing Chronic Tendon Pain by Metformin

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the current exploratory clinical trial is to determine the effect of oral ingestion of metformin (OIM) in non-diabetic patients with chronic Achilles tendon pain. The trial has two aims; 1) to assess the effects of OIM treatment on tendon pain, and 2) to determine the effects of OIM capsules on tendon healing and repair. Twenty participants will be treated with metformin capsules for 16 weeks combined with a home exercise program. A comparison group of 20 participants will be treated with placebo tablets along with home exercise program.

NCT ID: NCT06100809 Not yet recruiting - Fatigue Clinical Trials

Does Fatigue Coaching Improve Functioning and Fatigue in Resident Night Shifts

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

Emergency Medicine (EM) requires 24/7 staff coverage resulting in healthcare workers' circadian rhythm disruptions that impair clinical and cognitive performance, physical recovery, and contribute to burnout. Multiple well-being surveys continue to highlight EM's challenges with sleep impairment due to the nature of the specialty. Despite evidence that lifestyle strategies effectively optimize performance and recovery, EM residents have variable lifestyle choices to prepare for overnight shifts. This prospective randomized controlled trial will examine whether a pre-shift personalized fatigue-mitigation lifestyle coaching (PFMLC) for EM residents on overnight shifts minimizes the effects of circadian rhythm disruptions on performance and recovery compared to those who receive one-time passive information on lifestyle practices. All participants will receive lifestyle strategy materials on fatigue mitigation to improve performance. Residents' self-reported and biometric data will inform PFMLC in the active arm. Performance and recovery from night shifts will be assessed by changes in sleep, heart rate variability, readiness/recovery, alertness, cognitive performance, and mental health using Fitbit and validated measures.